Capecitabine with radiation is an effective adjuvant therapy in gastric cancers

doi:10.3748/wjg.v16.i29.3709

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 29

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4585)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

357

HTML

3699

Figures (1-1)

279

Tables (1-4)

250

Sum=4585

Aug 7, 2010 (publication date) through Feb 1, 2025

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Aug 7, 2010; 16(29): 3709-3715
Published online Aug 7, 2010. doi: 10.3748/wjg.v16.i29.3709

Table 1 Patient characteristics n (%)

	All patients (n = 108)	XRT (n = 33)	5FU-RT (n = 52)	Chemo alone (n = 23)	P-value¹ for XRT vs
	All patients (n = 108)	XRT (n = 33)	5FU-RT (n = 52)	Chemo alone (n = 23)	5FU-RT	Chemo alone
Age (yr)
Median	60	64	57	56	0.003²	0.03²
Inter-quartile range	49.5-66.0	57.7-68.8	48.0-63.7	49.3-65.7
Gender
Male	65 (60.2)	22 (66.7)	30 (57.7)	13 (56.5)	0.5	0.6
Female	43 (39.8)	11 (33.3)	22 (42.3)	10 (43.5)
ECOG
0	6 (5.6)	1 (3.0)	3 (5.8)	2 (8.7)	1.0	0.6
1	102 (94.4)	32 (97.0)	49 (94.2)	21 (91.3)
Helicobacter pylori status
Yes	36 (53.7)	16 (66.7)	15 (50.0)	5 (38.5)	0.3	0.2
No	31 (46.3)	8 (33.3)	15 (50.0)	8 (61.5)
Surgical margins
Positive	21 (19.4)	4 (12.1)	14 (26.9)	3 (13.0)	0.2	1.0
Negative	87 (80.6)	29 (87.9)	38 (73.1)	20 (87.0)
Stage
1 or 2	38 (35.2)	12 (36.4)	14 (26.9)	12 (52.2)	0.5	0.3
3 or 4	70 (64.8)	21 (63.6)	38 (73.1)	11 (47.8)
Grade
1 or 2	31 (28.7)	12 (36.4)	12 (23.1)	7 (30.4)	0.2	0.8
3	77 (71.3)	21 (63.6)	40 (76.9)	16 (69.6)
Albumin
< 30	12 (13.3)	4 (12.9)	4 (10.0)	4 (21.1)	0.7	0.5
≥ 30	78 (86.7)	27 (87.1)	36 (90.0)	15 (78.9)
CEA
Normal	50 (90.9)	17 (89.5)	24 (92.3)	9 (90.0)	1.0	1.0
High	5 (9.1)	2 (10.5)	2 (7.7)	1 (10.0)
Hemoglobin
< 10	26 (25.7)	8 (24.2)	14 (29.2)	4 (20.0)	0.8	1.0
≥ 10	75 (74.3)	25 (75.8)	34 (70.8)	16 (80.0)

¹All P-values calculated using Fisher’s exact test unless otherwise stated;

²P-value calculated using the Mann-Whitney U test. XRT: Capecitabine + radiation; 5FU-RT: 5-fluorouracil + radiation; ECOG: Eastern Cooperative Oncology Group status; CEA: Carcinoembryonic antigen.

Table 2 Recurrence-free survival and overall survival analysis

Variable	Categories/units	n	HR (95% CI)	P-value
Recurrence-free survival
Treatment	XRT	108	1
	5FU-RT		1.00 (0.508-1.959)	1.0
	Chemo only		1.05 (0.448-2.462)	0.9
Treatment	XRT	108	1
	5FU-RT		0.97¹ (0.477-1.966)	0.9
	Chemo only		1.03¹ (0.433-2.444)	0.9
Overall survival
Treatment	XRT	108	1
	5FU-RT		0.83 (0.411-1.681)	0.6
	Chemo only		1.13 (0.474-2.677)	0.8
Treatment	XRT	108	1
	5FU-RT		0.89¹ (0.428-1.856)	0.8
	Chemo only		1.19¹ (0.494-2.882)	0.7

¹Age-adjusted hazard ratio (HR). XRT: Capecitabine + radiation; 5FU-RT: 5-fluorouracil + radiation.

Table 3 Recurrence-free survival and overall survival analysis

Variable	Categories/units	Chemo alone		5FU-RT		XRT
Variable	Categories/units	HR (95% CI)	P-value¹	HR (95% CI)	P-value¹	HR (95% CI)	P-value¹
Recurrence-free survival
ECOG	0	1	0.9	1	1.0	E/N = 0/1	0.5
	1	0.92 (0.115-7.422)		1.01 (0.238-4.326)		NE
Gender	Male	1	0.9	1	0.2	1	0.5
	Female	0.91 (0.244-3.419)		1.58 (0.727-3.436)		0.65 (0.198-2.163)
Surgical margins	Positive	1	0.5	1	< 0.001	1	0.03
	Negative	0.51 (0.059-4.351)		0.16 (0.070-0.384)		0.27 (0.081-0.918)
Stage	1 or 2	1	0.1	1	0.2	1	0.06
	3 or 4	2.92 (0.724-11.773)		1.86 (0.749-4.633)		3.87 (0.853-17.586)
Grade of tumor	1, 2	1	0.3	1	0.09	1	0.3
	3	2.17 (0.444-10.636)		2.44 (0.836-7.099)		1.94 (0.515-7.288)
Overall survival
ECOG	0	1	0.8	1	0.9	E/N = 0/1	0.4
	1	0.78 (0.096-6.366)		0.95 (0.220-4.069)		NE
Gender	Male	1	1.0	1	0.2	8/22	0.7
	Female	1.02 (0.253-4.148)		1.63 (0.740-3.598)		0.78 (0.234-2.597)
Surgical margins	Positive	1	0.004	1	< 0.001	4/4	0.02
	Negative	0.10 (0.013-0.700)		0.26 (0.113-0.603)		0.25 (0.071-0.901)
Stage	1 or 2	1	0.2	1	0.1	2/12	0.06
	3 or 4	2.59 (0.646-10.412)		2.08 (0.778-5.557)		3.80 (0.829-17.397)
Grade of tumor	1, 2	1	0.4	1	0.06	3/12	0.4
	3	2.04 (0.418-9.944)		3.04 (0.903-10.239)		1.83 (0.482-6.980)

¹P -values were calculated using the Log-rank test. 5FU-RT: 5-fluorouracil + radiation; XRT: Capecitabine + radiation; ECOG: Eastern Cooperative Oncology Group status; E/N: Number of events/number of patients in the group; NE: Not estimable; HR: Hazard ratio.

Table 4 Subgroup analysis for overall and recurrence-free survival

Subgroup	Variable	Categories/units	n	Overall survival		Recurrence-free survival
Subgroup	Variable	Categories/units	n	HR (95% CI)	P-value	HR (95% CI)	P-value
Surgical margins = positive	Treatment	Chemo alone	21	1		1
Surgical margins = positive		5FU-RT/XRT		0.47 (0.100–2.191)	0.3	1.58 (0.206-12.154)	0.7
Stage T3/4	Treatment	Chemo alone	66	1		1
		5FU-RT/XRT		0.65 (0.294–1.454)	0.3	0.78 (0.352-1.709)	0.5
Node positive	Treatment	Chemo alone	94	1		1
		5FU-RT/XRT		0.92 (0.404–2.081)	0.8	1.10 (0.489-2.482)	0.8

5FU-RT: 5-fluorouracil + radiation; XRT: Capecitabine + radiation; HR: Hazard ratio.

Citation: Tham CK, Choo SP, Poon DYH, Toh HC, Ong SYK, Tan SH, Wang MLC, Foo KF. Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol 2010; 16(29): 3709-3715
URL: https://www.wjgnet.com/1007-9327/full/v16/i29/3709.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i29.3709